Evidence map›Paper›PMID 42355507›Full record

ArticleLife (Basel, Switzerland)2026

Selectively Targeting Leukemic MOLT-4 Cells by MTX-cIBR Conjugate: Mechanism of Action and Cellular Entry.

Sista Werdyani, Meagan E Weldele, Enade P Istyastono, Sofia M Harjana, Adi Hermawansyah, Wariya Nirachonkul, Dewi K Paramita, Teruna J Siahaan

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sista WerdyaniStudy Program of Doctor in Biotechnology, Graduate School, Universitas Gadjah Mada, Jl. Teknika Utara, Kocoran, Caturtunggal, Depok, Sleman, Yogyakarta 55281, Indonesia.
Meagan E WeldeleSimons Laboratories, Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA.
Enade P IstyastonoDepartment of Pharmacy, School of Medicine and Health Sciences, Atma Jaya Catholic University of Indonesia, Jl. Jenderal Sudirman, Karet Semanggi, Jakarta 12930, Indonesia.ORCID 0000-0002-8344-5587
Sofia M HarjanaDepartment of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sekip Utara, Depok, Sleman, Yogyakarta 55281, Indonesia.
Adi HermawansyahCell Culture Laboratory, Directorate of Innovation and Downstreaming, Universitas Muhammadiyah Yogyakarta, Jl. Brawijaya, Tamantirto, Kasihan, Bantul, Yogyakarta 55183, Indonesia.
Wariya NirachonkulDepartment of Medicinal Chemistry, The University of Kansas, 1251 Wescoe Dr, Lawrence, KS 66047, USA.ORCID 0009-0000-9833-8170
Dewi K ParamitaDepartment of Histology and Cell Biology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Jl. Farmako, Sekip Utara, Depok, Sleman, Yogyakarta 55281, Indonesia.ORCID 0000-0001-6759-8658
Teruna J SiahaanSimons Laboratories, Department of Pharmaceutical Chemistry, The University of Kansas, 2095 Constant Ave., Lawrence, KS 66047, USA.ORCID 0000-0001-7250-0627

Funding

NIH HHS 1R01AG071682-03NIH HHS 1R01AG082273-02
6 · The paper itself

Abstract

The ICAM-1-derived cIBR peptide selectively binds to the I-domain of LFA-1, a receptor highly expressed on leukemia T cells; thus, the MTX-cIBR conjugate can be used to target methotrexate (MTX) to leukemic T cells and reduce its off-target toxicity. However, the uptake, biological mechanism, and selectivity of MTX-cIBR compared with unconjugated MTX remain unclear. Therefore, this study is aimed at evaluating the uptake, cytotoxicity, selectivity, apoptosis, cell cycle effects, and

Indexed as

cell cyclecIBRdrug conjugatesleukemic T cellLFA-1MOLT-4MTXMTX-cIBRtargeted delivery

Identifiers

PMID42355507
PMCPMC13301118

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.